Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status?

Medical Science Monitor

Volumn 16, Issue 2, 2010, Pages

  Sypniewska, Grazyna ^a   Sobanska, Izabela ^a   Pater, Agnieszka ^a   Kȩdziora Kornatowska, Kornelia ^a   Nowacki, Wieslaw ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Biomarkers of bone turnover; Elderly women; Hip fractures; Osteoporosis; Osteoprotegerin; Vitamin 25 OHD3

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCIFEDIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FRACTURE HEALING; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS;

AGED; AGED, 80 AND OVER; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPROTEGERIN; VITAMIN D;

EID: 76049088310     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Garnero P, Delmas PD: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact, 2004; 4: 50-63
2. Eastell R, Hannon RA: Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc, 2008; 67: 157-62
3. Łukaszkiewicz J, Karczmarewicz E, Płudowski P et al: EPOLOS Group. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study. Med Sci Monit, 2008; 14(12): PH65-70
4. Browner W, Lui L, Cummings S: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab, 2001; 86: 631-37
5. Jorgensen HL, Kusk P, Madsen B et al: Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab, 2004; 22: 132-38
6. Rogers A, Eastell A: Circulating osteoprotegerin and receptor activator of nuclear factor kappa B ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab, 2005; 90: 6323-31
7. Kearns AE, Khosla S, Kostenuik P: RANKL and OPG: regulation of bone remodeling in health and disease. Endocrine Rev, 2008; 29: 155-92
8. Mezquita-Raya R, Higuera M, Gracia D: The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int, 2005; 16: 1368-74
9. Stejskal D, Bartek J, Pasterkova R: Osteoprotegerin, RANK, RANKL. Biomed Papers, 2001; 145: 61-64
10. Dobnig H, Piswanger-Sölkner JC, Obermayer-Pietsch B et al: Hip and non-vertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab, 2007; 92: 1678-86
11. Abdallah BM, Stilgren LS, Nissen N et al: Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int, 2005; 76: 90-97
12. Tsangari H, Findlay DM, Kuliwaba JS et al: Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone, 2004; 35: 334-42
13. Chiba Y, Onouchi T, Ikeda T et al: Implications of measuring soluble receptor activators of nuclear factor KappaB ligand and osteoprotegerin in bone metabolism of elderly women. Gerontology, 2 009; 55(3): 275-80
14. Schett G, Kiechl S, Redlich K et al: Soluble RANKL and risk of nontraumatic fracture. JAMA, 2004; 291: 1108-13
15. Moffett SP, Oakley JI, Cauley JA et al: Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women. J Clin Endocrinol Metab, 2008; 93: 2002-8
16. Michaëlsson K, Melhus H, Ferm H et al: Genetic liability to fractures. Arch Intern Med., 2005; 165: 1825-30
17. Rogers A, Saleh G, Hannon RA: Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. Clin Endocrinol Metab, 2002; 87: 4470-75
18. Indridason OS, Franzson L, Sigurdsson G: Serum osteoprotegerin and relationship with bone mineral density and markers of bone turnover. Osteoporos Int, 2005; 16: 417-23
19. Dai Y, Shen L: Relationship between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl), 2007; 120: 2017-21
20. Takahashi M, Naitou K, Ohishi T, Nagano A: Comparison of biochemical markers of bone turnover and bone mineral density between hip fracture and vertebral fracture. J Clin Densitom, 2003; 6: 211-18
21. Camacho PM, Lopez NA: Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med., 2008; 46: 1345-57
22. Sypniewska G, Chodakowska-Akolinska G: Bone turnover markers and estradiol level in postmenopausal women. Clin Chem. Lab Med., 2000; 38: 1115-19
23. Gerdhem P, Ivaska KK, Alatalo SL et al: Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res, 2004; 19: 386-93
24. Obrant KJ, Ivaska KK, Gerdhem P et al: Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone, 2005; 36: 786-92
25. Seibel MJ: Biochemical markers of bone turnover Part I: Biochemistry and variability. Clin Biochem Rev, 2005; 26: 97-116
26. Halleen JM, Alatalo SL, Janckila AJ et al: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem, 2001; 47: 597-600
27. Janckila AJ, Takahashi K, Sun SZ, Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem, 2001; 47: 74-80
28. Chen CJ, Chao TY, Janckila AJ et al: Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese childrena novel marker for bone growth. J Pediatr Endocrinol Metab, 2005; 18: 55-62
29. Ivaska K, Gerdhem P, Akesson K et al: Effect of fracture on bone turnover markers: A longitudinal study comparing marker levels before and after injury in 113 women. J Bone Miner Res, 2007; 22: 1155-64
30. Akesson K, Vergnaud P, Delmas PD, Obrant KJ: Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone, 1995; 16: 427-30
31. Kon T, Cho TJ, Aizawa T et al: Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing, J Bone Miner Res, 2001; 16: 1004-14